ALK2 (ACVR1) Kinase Assay Kit

Catalog #
79605
$535 *
Size: 96 Reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The ALK2 (ACVR1) Kinase Assay Kit is designed to measure ALK2 (activin receptor-like kinase-2) kinase activity for screening and profiling applications using ADP-Glo™ as a detection reagent. The assay kit comes in a convenient 96-well format, with enough purified recombinant ALK2 (amino acids 147-509), casein, ATP, and kinase assay buffer for 100 enzyme reactions.

Need us to run inhibitor screens or profile your compounds against ALK2? Check out our Kinase Screening Services.

Synonyms
Activin receptor-like kinase 2 (ACVRLK2), ACVRLK2, FOP, SKR1, TSRI, ALK
Product Info
Storage and Usage
Citations
Assay Kit Format
Luminescent
Materials Required But Not Supplied
  • ADP-Glo™ Kinase Assay (Promega #V6930) 
  • DTT (Dithiothreitol), 1M, optional
  • Microplate reader capable of reading luminescence 
  • Adjustable micropipettor and sterile tips 
  • 30°C incubator
Format
Catalog # Name Amount Storage
40019 ALK2 (ACVR1), GST-Tag 10 µg -80°C
79334 5x Kinase Buffer 1 1.5 ml -20°C
79686 500 µM ATP 100 µl -20°C
79550 Casein (5 mg/ml) 100 µl -20°C
79696 White 96-well plate 1 Room Temp

*The concentration of the protein is lot-specific and will be indicated on the tube.

UniProt #
Q04771
Background

ALK2 (activin receptor-like kinase-2), also known as ACVR1 (activin A receptor, type 1) is a protein of the BMP (bone morphogenetic protein) and TGFβ (transforming growth factor beta) family, and is a type I receptor. Activin signaling occurs by binding activin to heteromeric complexes of receptor type I and type II, with receptor type I being responsible for signaling and type II for ligand binding. SMAD1 (mothers against decapentaplegic homolog 1)/2/3/6 are activated by ALK2. This protein is involved in the development of several organs, such as heart, nervous system, and bone. Dysfunction of ALK2 can result in a set of rare diseases, namely fibrodysplasia ossificans progressive (FOP). ALK2 is also linked to DIPG (diffuse intrinsic pontine glioma). The development of ALK2 inhibitors has been hindered by the close similarity in the kinase domain of the 7 known ALK, with particular attention needed on inhibition of ALK5, which can result in cardiac toxicity. Clinical trials are ongoing and will pave the way for further studies using ALK2-specific inhibitors.

References

Cunha S. I. and Pietras K., 2011 Blood 117(26): 6999–7006.
Minsung K., et al., 2017 Biochemical and Biophysical Research Communications 492(1):121-127.
Rooney L. and Jones C., 2021 ACS Omega 6(32):20729-20734.